Back to Journals » Cancer Management and Research » Volume 4

New drugs and combinations for the treatment of soft-tissue sarcoma: a review

Authors Somaiah, von Mehren M

Received 12 July 2012

Accepted for publication 27 September 2012

Published 23 November 2012 Volume 2012:4 Pages 397—411

DOI https://doi.org/10.2147/CMAR.S23257

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2


Neeta Somaiah,1 Margaret von Mehren2

1Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA

Abstract: Sarcomas are a heterogeneous group of solid tumors arising from either soft tissues or bone, accounting for approximately 1% of all cancers in adults. Management of these diseases has changed little over the past 10 years, with the exception of treatment of gastrointestinal stromal tumors. Reasons for this stagnation include multiple histologies commonly grouped together in clinical trials limiting the understanding of benefit of treatment and limited investigation of molecular targeted therapies. More recently, advances in molecular pathogenesis, the advent of novel and targeted therapeutics, and increasing collaborations between sarcoma investigators has helped move the field forward in the right direction. Here, we review the recent data on novel agents tested for the management of adult soft-tissue sarcomas, excluding gastrointestinal stromal tumors.

Keywords: soft tissue sarcoma, clinical trials, trabectedin, palifosfamide, pazopanib

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]